A detailed history of Te Ahumairangi Investment Management LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Te Ahumairangi Investment Management LTD holds 13,339 shares of VRTX stock, worth $6.16 Million. This represents 1.09% of its overall portfolio holdings.

Number of Shares
13,339
Previous 13,889 3.96%
Holding current value
$6.16 Million
Previous $6.51 Million 5.24%
% of portfolio
1.09%
Previous 1.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 21, 2024

SELL
$460.0 - $505.78 $253,000 - $278,179
-550 Reduced 3.96%
13,339 $6.17 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $331,924 - $410,272
-845 Reduced 5.74%
13,889 $6.51 Million
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $191,614 - $209,657
470 Added 3.3%
14,734 $6.16 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $1.41 Million - $1.69 Million
-4,105 Reduced 22.35%
14,264 $5.8 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $1.33 Million - $1.42 Million
-3,925 Reduced 17.61%
18,369 $6.39 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $133,628 - $149,561
425 Added 1.94%
22,294 $7.85 Million
Q4 2022

Feb 08, 2023

BUY
$285.76 - $321.48 $1.68 Million - $1.89 Million
5,894 Added 36.9%
21,869 $6.32 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $9,584 - $10,693
35 Added 0.22%
15,975 $4.63 Million
Q2 2022

Aug 16, 2022

BUY
$234.96 - $292.55 $272,553 - $339,358
1,160 Added 7.85%
15,940 $4.49 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $223,634 - $263,579
1,010 Added 7.33%
14,780 $3.86 Million
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $2.44 Million - $3.08 Million
13,770 New
13,770 $3.02 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Te Ahumairangi Investment Management LTD Portfolio

Follow Te Ahumairangi Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Te Ahumairangi Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Te Ahumairangi Investment Management LTD with notifications on news.